- Datasheet
- Specific References
- Protocols
Overview
-
Product nameAnti-HtrA2 / Omi antibody
See all HtrA2 / Omi primary antibodies -
DescriptionRabbit polyclonal to HtrA2 / Omi
-
Tested applicationsSuitable for: WB, ICC/IF, IHC-Pmore details
-
Species reactivityReacts with: Human
-
Immunogen
Synthetic peptide corresponding to 16 amino acids near the C-terminus of human OMI.
-
Positive control
- U937 cell lysate.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C.
-
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: PBS -
Concentration information loading... -
PurityIgG fraction
-
Purification notesPurified by Ion exchange chromatography.
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
Applications
Our Abpromise guarantee covers the use of ab36854 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | Use a concentration of 0.5 - 1 µg/ml. Detects a band of approximately 48 kDa (predicted molecular weight: 49 kDa). | |
| ICC/IF | Use a concentration of 20 µg/ml. | |
| IHC-P | Use a concentration of 2 µg/ml. |
Target
-
FunctionSerine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.
-
Tissue specificityIsoform 1 is ubiquitous. Isoform 2 is expressed predominantly in the kidney, colon and thyroid.
-
Involvement in diseaseDefects in HTRA2 are the cause of Parkinson disease type 13 (PARK13) [MIM:610297]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
-
Sequence similaritiesBelongs to the peptidase S1B family.
Contains 1 PDZ (DHR) domain. -
DomainThe mature N-terminus is involved in the interaction with XIAP.
The PDZ domain mediates interaction with MXI2. -
Post-translational
modificationsAutoproteolytically activated. -
Cellular localizationMitochondrion intermembrane space. Mitochondrion membrane. Predominantly present in the intermembrane space. Released into the cytosol following apoptotic stimuli, such as UV treatment, and stimulation of mitochondria with caspase-8 truncated BID/tBID.
- Information by UniProt
-
Database links
- Entrez Gene: 27429 Human
- Omim: 606441 Human
- SwissProt: O43464 Human
- Unigene: 469045 Human
- Unigene: 744841 Human
-
Alternative names
- High temperature requirement protein A2 antibody
- HTRA 2 antibody
- HtrA like serine protease antibody
see all
Anti-HtrA2 / Omi antibody images
-
Western blot - HtrA2 / Omi antibody (ab36854)Anti-HtrA2 / Omi antibody (ab36854) at 1 µg/ml + U937 cell lysate
Predicted band size : 49 kDa
Observed band size : 48 kDa (why is the actual band size different from the predicted?)
Additional bands at : 35 kDa (possible isoform). -
Immunocytochemistry/ Immunofluorescence-Anti-HtrA2 / Omi antibody(ab36854)Immunofluorescence of OMI in Human Liver cells using ab36854 at 20 ug/ml.
Protocols
References for Anti-HtrA2 / Omi antibody (ab36854)
ab36854 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"